Compare Novo Nordisk A/S (NVO) vs Impinj Inc (PI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Impinj Inc — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Impinj Inc trades at $137.09 (market cap $4.19B). The key difference: Novo Nordisk A/S is far larger — about 52.6× Impinj Inc's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Impinj Inc pays none. Which is the better fit depends on your goals.
| NVO | PI | |
|---|---|---|
Market Cap | $220.53B | $4.19B |
Sector | Health | Technology |
52-Week High | $71.70 | $241.91 |
52-Week Low | $35.29 | $91.34 |
Enterprise Value | $239.49B | $4.33B |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
Impinj (PI) trades at $137.72, down 0.33% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The company reported mixed Q1 2026 results with $0.14 EPS beating expectations but faces profitability challenges with negative net income margins. Analyst sentiment remains strongly positive with 73% buy ratings and a $167.50 consensus price target, representing 22% upside potential from current levels.
While analyst optimism and RFID market positioning provide upside potential, significant risks include persistent negative profitability, high valuation multiples, and recent insider selling. The stock's technical weakness near key support levels at $136-$135 suggests near-term caution despite long-term growth prospects in the expanding RFID market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
